Earlier onset of tumoral angiogenesis in matrix metalloproteinase-19- deficient mice

Cancer Research

Volumn 66, Issue 10, 2006, Pages 5234-5241

  Jost, Maud ^a   Folgueras, Alicia R ^c   Frérart, Françoise ^a   Pendas, Alberto M ^c,d   Blacher, Silvia ^a   Houard, Xavier ^a   Berndt, Sarah ^a   Munaut, Carine ^a   Cataldo, Didier ^a   Alvarez, Jésus ^c   Melen Lamalle, Laurence ^a   Foidart, Jean Michel ^a,b   López Otín, Carlos ^c   Noël, Agnès ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Department of Gynecology   (Belgium)

^c DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^d Centro de Investigacion del Cancer   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 19; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER INVASION; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VIVO STUDY; KERATINOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN TUMOR; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; COLLAGEN; DRUG COMBINATIONS; FEMALE; LAMININ; MALE; METALLOENDOPEPTIDASES; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PROTEOGLYCANS; SKIN NEOPLASMS; STROMAL CELLS;

EID: 33744940015     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4315     Document Type: Article

References (48)

1. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
2. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000; 14:2123-33.
3. Konttinen YT, Ainola M, Valleala H, et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis 1999;58:691-7.
4. Folgueras AB, Pendas AM, Sanchez LM, Lopez-Otin C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 2004;48:411-24.
5. Noel A, Maillard C, Rocks N, et al. Membrane associated proteases and their inhibitors in tumour angiogenesis. J Clin Pathol 2004;57:577-84.
6. Handsley MM, Edwards DR. Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer 2005; 115:849-60.
7. Sounni NE, Noel A. Membrane type-matrix metalloproteinases and tumor progression. Biochimie 2005; 87:329-42.
8. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516.
9. McQuibban GA, Gong JH, Tam EM, McCulloch CAG, Clark-Lewis I, Overall CM. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000;289:1202-6.
10. McQuibban GA, Butler GS, Gong JH, et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 2001;276: 43503-8.
11. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
12. Puente XS, Lopez-Otin C. A genomic analysis of rat proteases and protease inhibitors. Genome Res 2004;14: 609-22.
13. Lopez-Otin C, Overall CM. Protease degradomics: a new challenge for proteomics. Nat Rev Mol Cell Biol 2002;3:509-19.
14. Zucker S, Pei DQ, Cao J, Lopez-Otin C. Membrane type-matrix metalloproteinases (MT-MMP). Cell Surface Proteases 2003;54:1-74.
15. Pendas AM, Knauper V, Puente XS, et al. Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J Biol Chem 1997;272:4281-6.
16. Sedlacek R, Mauch S, Kolb B, et al. Matrix metalloproteinase MMP-19 (RASI 1) is expressed on the surface of activated peripheral blood mononuclear cells and is detected as an autoantigen in rheumatoid arthritis. Immunobiology 1998;198:408-23.
17. Yang MZ, Kurkinen M. Cloning and characterization of a novel matrix metalloproteinase (MMP), CMMP, from chicken embryo fibroblasts-CMMP, Xenopus XMMP, and human MMP19 have a conserved unique cysteine in the catalytic domain. J Biol Chem 1998;273:17893-900.
18. Mueller MS, Mauch S, Sedlacek R. Structure of the human MMP-19 gene. Gene 2000;252:27-37.
19. Stracke JO, Fosang AJ, Last K, et al. Matrix metalloproteinases 19 and 20 cleave aggrecan and cartilage oligomeric matrix protein (COMP). FEBS Lett 2000;478: 52-6.
20. Stracke JO, Hutton M, Stewart M, et al. Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19-evidence for a role as a potent basement membrane degrading enzyme. J Biol Chem 2000;275:14809-16.
21. Djonov V, Hogger K, Sedlacek R, Laissue J, Draeger A. MMP-19: cellular localization of a novel metalloproteinase within normal breast tissue and mammary gland tumours. J Pathol 2001;195:147-55.
22. Impola U, Toriseva M, Suomela S, et al. Matrix metalloproteinase-19 is expressed by proliferating epithelium but disappears with neoplastic dedifferentiation. Int J Cancer 2003;103:709-16.
23. Impola U, Jeskanen L, Ravanti L, et al. Expression of matrix metalloproteinase (MMP)-7 and MMP-13 and loss of MMP-19 and p16 are associated with malignant progression in chronic wounds. Br J Dermatol 2005;152:720-6.
24. Pendas AM, Folgueras AR, Llano E, et al. Diet-induced obesity and reduced skin cancer susceptibility in matrix metalloproteinase 19-deficient mice. Mol Cell Biol 2004;24:5304-13.
25. Kolb C, Mauch S, Krawinkel U, Sedlacek R. Matrix metalloproteinase-19 in capillary endothelial cells: expression in acutely, but not in chronically, inflamed synovium. Exp Cell Res 1999;250:122-30.
26. Bajou K, Masson V, Gerard RD, et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: implications for antiangiogenic strategies. J Cell Biol 2001;152:777-84.
27. Fusenig NE. Growth and differentiation characteristics of transformed keratinocytes from mouse and human skin in vitro and in vivo. In: Breitkreutz D, Dzarlieva RT, Boukamp P, Bohnert A, Tilgen W, editors. J Invest Dermatol 1983;81:168-75s.
28. Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4:923-8.
29. Bajou K, Masson V, Gerard RD, et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: implications for antiangiogenic strategies. J Cell Biol 2001;152:777-84.
30. Bajou K, Maillard C, Jost M, et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 2004;23:6986-90.
31. Kapur JN, Sahoo PK, Wong AKC. A new method for Gray-level picture thresholding using the entropy of the histogram. Comput Vis Graph Image Process 1985;29: 273-85.
32. Kohler R. A segmentation system based on thresholding. Comput Graph Image Process 1985;15:319-38.
33. Passaniti A, Taylor RM, Pili R, et al. Methods in laboratory investigation-a simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement-membrane, heparin, and fibroblast growth-factor. Lab Invest 1992;67: 519-28.
34. Mueller MM, Fusenig NE. Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells. Differentiation 2002;70:486-97.
35. Mueller MM, Fusenig NE. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4:839-49.
36. Hieta N, Impola U, Lopez-Otin C, Saarialho-Kere U, Kahari VM. Matrix metalloproteinase-19 expression in dermal wounds and by fibroblasts in culture. J Invest Dermatol 2003;121:997-1004.
37. Sadowski T, Dietrich S, Koschinsky F, et al. Matrix metalloproteinase 19 processes the laminin 5γ2 chain and induces epithelial cell migration. Cell Mol Life Sci 2005;62:870-80.
38. Titz B, Dietrich S, Sadowski T, Beck C, Petersen A, Sedlacek R. Activity of MMP-19 inhibits capillary-like formation due to processing of nidogen-1. Cell Mol Life Sci 2004;61:1826-33.
39. Sadowski T, Dietrich S, Koschinsky F, Sedlacek R. Matrix metalloproteinase 19 regulates insulin-like growth factor-mediated proliferation, migration, and adhesion in human keratinocytes through proteolysis of insulin-like growth factor binding protein-3. Mol Biol Cell 2003;14:4569-80.
40. Pozzi A, Moberg PE, Miles LA, Wagner S, Soloway P, Gardner HA. Elevated matrix metalloprotease and angiostatin levels in integrin α1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci U S A 2000;97:2202-7.
41. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000;103: 481-90.
42. Andarawewa KL, Boulay A, Masson W, et al. Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression. Cancer Res 2003;63: 5844-9.
43. Masson V, de la Ballina LR, Munaut C, et al. Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. FASEB J 2005;19:234-6.
44. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2: 737-44.
45. Chantrain CF, Shimada H, Jodele S, et al. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res 2004;64:1675-86.
46. Balbin M, Fueyo A, Tester AM, et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 2003;35:252-7.
47. McCawley LJ, Crawford HC, King LE, Mudget J, Matrisian LM. A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res 2004;64:6965-72.
48. Rudolph-Owen LA, Chan R, Muller WJ, Matrisian LM. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. Cancer Res 1998; 58:5500-6.